Project Grant R01AI201741
Award Date 8/19/26
Completion Date 7/31/31
Dollars Obligated $635K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Rochester, NY 14642, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Mayo Clinic $242,100 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and validate a translational precision-cut lung slice (PCLS) model for testing host-response mechanisms and therapeutic agents in Pneumocystis pneumonia. The project, titled "A Translational Precision-Cut Lung Slice Model for Host-Response and Therapeutic Testing in Pneumocystis Pneumonia,"...
- The National Institute of Allergy and Infectious Diseases awarded Mayo Clinic $441,100 on July 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research targeting phosphoglucomutase in Pneumocystis pneumonia. The research addresses the glucan-rich cell wall of Pneumocystis, which synthesizes β-glucans from uridine diphosphate glucose, a pathway requiring phosphoglucomutase (PGM) to interconvert glucose-6-phosphate and glucose-1-phosphate. Prior...
- The National Institute of Allergy and Infectious Diseases awarded The Trustees of Columbia University in the City of New York $452,375 on June 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify transcription factors that promote pulmonary infection by opportunistic pathogens. The recipient will conduct research to determine how the transcription factor RpoN responds to environmental signals in Pseudomonas aeruginosa and Klebsiella pneumoniae, and how...
- The National Institute of Allergy and Infectious Diseases awarded the University of Rochester $1,042,346 on January 28, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify key age-associated immune pathways in extremely low gestational age neonates (ELGANs) that can be targeted for therapeutic intervention. The project investigates critical developmental windows and underlying processes in ELGANs' immune trajectories, specifically examining how T cell...
- The National Institute of Allergy and Infectious Diseases awarded the University of Rochester $148,626 on November 14, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research elucidating the mechanisms and implications of BST2 antagonism by SARS-CoV-2. The research examines how SARS-CoV-2 evades BST2/tetherin, a key cellular intrinsic immune factor that restricts enveloped viruses by tethering nascent virions to cell surfaces and facilitating adaptive...
- The National Institute of Allergy and Infectious Diseases awarded Albany Medical College $604,681 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the molecular and epigenetic mechanisms of endothelial inflammatory memory in sepsis survivors vulnerable to secondary infections, particularly pneumonia. The recipient will examine how transcription factors STAT3 and JUNB, and the histone methyltransferase EZH2, establish and maintain...
- The National Institute of Allergy and Infectious Diseases awarded the University of Rochester $162,000 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research on genome organization in dendritic cell development. The project, titled "Elucidating the Role of Genome Organization in CDC1 Development," investigates how the cohesin protein complex controls the epigenetic regulation of type 1 conventional dendritic cell (CDC1)...
- The National Institute of Allergy and Infectious Diseases awarded New York University $827,768 on August 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how microbial exposure influences the persistence of long-lived plasma cells in the small intestinal lamina propria. The research will employ imaging and single-cell profiling to define how microbial exposures shape the generation, turnover, and function of long-lived plasma cells by comparing...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded the Regents of the University of Michigan $194,400 on April 1, 2026 under the Allergy and Infectious Diseases Research program (CFDA 93.855). The project examines the role of organelle membrane contact sites in macrophage antifungal immune responses, with particular focus on Candida albicans infection. Preliminary data indicate that the endoplasmic reticulum stress sensor IRE1A...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Arizona a Project Grant of $3,075,549 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 28, 2025, with a completion date of June 30, 2029. This research initiative investigates airway innate immune responses to Coccidioides infection, a serious fungal disease commonly known as valley fever that is expanding geographically across the United States. The research focuses on...